Pre Exposure Prophylaxis News and Research

RSS

HIV infection risk reduced by same drugs that treat HIV

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

11 Jul 2012

New Lancet issue focuses on HIV ahead of AIDS 2012 conference

This week's issue of the Lancet "has an HIV theme ahead of the International AIDS Society meeting in Washington, D.C., ... on July 22-27," a Lancet editorial states, noting, "The issue of antiretrovirals for prevention, specifically pre-exposure prophylaxis, is presently under intense debate."

30 Jun 2012

USA Today features Q&A on Truvada's potential as prevention tool

USA Today features a Q&A on Truvada, an antiretroviral drug that a Food and Drug Administration (FDA) panel in May recommended be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.

27 Jun 2012

Breast milk protects against oral transmission of HIV

More than 15 percent of new HIV infections occur in children. Without treatment, only 65 percent of HIV-infected children will live until their first birthday, and fewer than half will make it to the age of two. Although breastfeeding is attributed to a significant number of these infections, most breastfed infants are not infected with HIV, despite prolonged and repeated exposure.

15 Jun 2012

Pre-exposure preventive treatment may be effective against suspected HIV

While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ (Canadian Medical Association Journal).

29 May 2012

Bill introduced in U.S. Senate is latest push to award prizes for new drug development

"As Washington prepares for a major international AIDS conference this summer, developments on the drug front are once again elevating the subject of the continuing epidemic in the public eye," CQ HealthBeat reports.

22 May 2012

IAS’ XIX International AIDS Conference to take place in Washington D.C.

This summer, more than 25,000 leading scientists, public health experts, policy-makers, community members, and experts in the HIV/AIDS field from around the world will gather in our nation's capital for the International AIDS Society's XIX International AIDS Conference.

19 May 2012

Newspapers examine concerns surrounding possible FDA approval of Truvada for PrEP

The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.

16 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

AIDS, health groups submit comments to FDA prior to agency's review of PrEP

"In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/tenofovir disoproxil fumarate [TDF/FTC] ... as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women," a press release from AVAC: Global Advocacy for HIV Prevention states.

3 May 2012

FDA approval of TDF/FTC as PrEP for HIV infection receives support

In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women.

2 May 2012

Research roundup: Caring for dual eligibles; Antitrust policy and the health law

Using data from the Centers for Disease Control and Prevention (CDC), this report notes a systematic difference in life expectancy across region and race. "Within in each sex-race group, there are striking geographical differences in the probability of survival to age 70. ... These differences are larger for males than females within each race and larger for blacks than whites within each sex."

21 Apr 2012

WHO releases guidance on couples testing, counseling, including ART for discordant couples

The WHO on Wednesday released its new 54-page "Guidance on couples HIV testing and counselling, including antiretroviral therapy (ART) for treatment and prevention in serodiscordant couples: Recommendations for a public health approach," according to the Center for Global Health Policy's "Science Speaks" blog.

20 Apr 2012

Researchers, advocates meet in Sydney to discuss state of microbicide, HIV prevention research

"Three decades after the full onset of the global HIV tragedy, science appears to finally be developing preventative measures, including microbicides that would thwart infections in the first place, according to individuals at" the biennial International Microbicides Conference in Sydney, the Asia Sentinel writes.

19 Apr 2012

Anti-HIV pill could prevent thousands of new infections: Study finds

A once daily pill to prevent HIV infection could significantly reduce the spread of the AIDS-causing virus. However it would only be cost-effective if limited to men at very high risk for HIV infection, according to a new study.

18 Apr 2012

No added HIV risk with hormonal contraceptives

An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.

18 Apr 2012

International Microbicides Conference to discuss state of HIV prevention research

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis.

17 Apr 2012

AHF calls on FDA Commissioner Hamburg to step down

AIDS Healthcare Foundation (AHF), the nation's largest HIV/AIDS organization, today called on Food and Drug Administration (FDA) Commissioner Margaret Hamburg to step down in response to the agency's gross mismanagement of new product reviews and a lack of transparency.

29 Mar 2012

Experts discuss significant findings from CROI in video interview

This post in the AIDS.gov blog provides video of Ron Valdiserri, deputy assistant secretary of health for infectious diseases, interviewing Jonathan Mermin, director of the CDC Division of HIV/AIDS Prevention, at the recent 19th Conference on Retroviruses and Opportunistic Infections.

22 Mar 2012

Challenges to achieving an AIDS-free generation

In a plenary presentation at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle on Wednesday, Dorothy Mbori-Ngacha of UNICEF examined the challenges to reaching the goal of an AIDS-free generation, by "eliminating 90 percent of HIV infections among children by 2015," and "outlined the four pillars of achieving that goal," including preventing HIV among women, preventing unintended pregnancies, preventing mother-to-child transmission (PMTCT), and supporting HIV-positive women and their families, the Center for Global Health Policy's "Science Speaks" reports.

9 Mar 2012